SHANGHAI, Jan. 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. Under the terms of the agreement, WuXi Biologics leverages its proprietary antibody discover ...

BioNTech SE (NASDAQ:BNTX) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Ugur Sahin - CEO Ryan Richardson - Chief Strategy Officer Conference Call Participants Jess Fye - J.P. Morgan Jess Fye Great. Good morning, everyone. My name is Jess Fye. I am a Senior Biotech Analyst at J.P. Morgan, and we’re continuing the conference today with BioNTech. I am joined by the company's CEO, Dr. Ugur Sahin. He is going to give a presentation on the company and then we are g ...

BioNTech SE (NASDAQ:BNTX) 42nd Annual J.P. Morgan Healthcare Conference January 9, 2024 12:00 PM ET Company Participants Ugur Sahin - CEO Ryan Richardson - Chief Strategy Officer Conference Call Participants Jess Fye - J.P. Morgan Jess Fye Great. Good morning, everyone. My name is Jess Fye. I am a Senior Biotech Analyst at J.P. Morgan, and we’re continuing the conference today with BioNTech. I am joined by the company's CEO, Dr. Ugur Sahin. He is going to give a presentation on the company and then we are g ...

Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion (unaudited) in cash, cash equivalents and security investments Expects full year 2024 revenues of approximately €3 billionPresentation and webcast at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 6:00 p.m. CET/ 12:00 p.m. ET Mainz, Germany, January 9, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (NASDAQ:BNTX ...

Marcin Klapczynski/iStock via Getty Images At a Glance In my previous analysis of Germany-based BioNTech (NASDAQ:BNTX), I underscored its potential for growth in immunotherapy and the importance of its oncology-focused initiatives. Since then, while their COVID-19 vaccine sales have declined further, the company has made notable progress in diversifying its portfolio. This is evident in their strategic expansion into antibody-drug conjugates (ADCs) and the acquisition of MediLink Therapeutics' ADC techn ...

U. J. Alexander BioNTech (NASDAQ:BNTX) was already starting to gain some recognition for its pioneering work in mRNA technology when it signed an agreement with Pfizer (PFE) to develop a mRNA-based vaccine to prevent the flu in 2018. However, few knew at the time that the relationship would pave the way for another collaboration that would go on to produce the highest-selling pharmaceutical product in a single year, with $36.8 billion in 2021 sales, the COVID-19 vaccine. Pfizer describes how it and BioNTech ...

BioNTech SE (NASDAQ:BNTX) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Yaron Werber - TD Cowen Jessica Fye - JPMorgan Bill Maughan - Canaccord Genuity Simon Baker - Redb ...

BA.2.86 remains low worldwide Growing dominance of the XBB-descendent EG.5.1 XBB.1.5-adapted monovalent vaccine elicits potent neutralization against various sublineages: XBB.1.5, EG.5.1, BA.2.86, XBB.1.16 and XBB.2.3 1. Partnered with Pfizer. 2.COMIRNATY approved for prevention of COVID-19 as a single dose for individuals 5 years of age and older and as a 3-dose series in individuals 6 months through 4 years of age. 3. COMIRNATY may be administered as a booster in people aged 12 years and older who have re ...

| --- | --- | --- | --- | |-----------------------------------------|-------|--------------------------------------|---------------------| | (in millions €) Assets | Note | September 30, \n2023 (unaudited) | December 31, \n2022 | | Non-current assets | | | | | Intangible assets | 5, 7 | 665.5 | 158.5 | | Goodwill | 5 | 365.6 | 61.2 | | Property, plant and equipment | | 728.9 | 609.2 | | Right-of-use assets | | 197.0 | 211.9 | | Other financial assets | 8 | 1,292.7 | 80.2 | | Other non-financial assets | | 0 ...

BioNTech SE (NASDAQ:BNTX) Q2 2023 Earnings Conference Call August 7, 2023 8:00 AM ET Company Participants Victoria Meissner - VP, Strategy & IR Ugur Sahin - Co-Founder & CFO Ozlem Tureci - Chief Medical Officer & Co-Founder Jens Holstein - CFO Ryan Richardson - Chief Strategy Officer Conference Call Participants Daina Graybosch - Leerink Partners Tazeen Ahmad - Bank of America Chris Shibutani - Goldman Sachs Brendan Smith - TD Cowen Terence Flynn - Morgan Stanley Bill Maughan - Canaccord Simon Baker - Redbu ...